GU Cancers 2024 | Enhancing immunotherapy efficacy in bladder cancer

Girish Kulkarni, MD, PhD, University of Toronto, Ontario, Canada, discusses the need for combination immunotherapy strategies for urothelial carcinoma. Findings from the SWOG S1605 (NCT02844816), KEYNOTE-057 (NCT02625961) and SunRISe-1 (NCT04640623) trials have demonstrated how immunotherapy as monotherapy is insufficient. Trials such as cohort C of the KEYNOTE-057 and CORE-001 (NCT04387461) studies will assess novel strategies incorporating immunotherapies. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.